RXFP4 and nasopharyngeal carcinoma: Consequently, we treated the INSL5‐overexpressing NPC PDX mouse model with anti‐INSL5 and anti‐GPCR142 neutralizing antibodies, and as expected, these treatments markedly inhibited tumor growth.